In response to the Office Action of February 6, 2007, please amend the application as follows:

IN THE CLAIMS:

1-104. (Cancelled)

105. (New) An isolated R1 allelic variant having SEQ ID NO: 1 of Signal Transducer and Activator of Transcription-6 (STAT-6) Gene for use in predicting susceptibility of a subject to atopic asthma.

106. (New) The isolated allelic variant according to claim 105, wherein the subject is human.

107. (New) An isolated R3 alellic variant of SEQ ID NO: 2 of Signal Transducer and Activator of Transcription-6 (STAT-6) Gene for use in predicting susceptibility of a subject to atopic asthma.

108. (New) The isolated allelic variant according to claim 107, wherein the subject is human.

109. (New) The isolated allelic variant according to claim 105, wherein CA nucleotide repeat is on 17 allele of R1 locus and on 15 allele of R3 locus of the STAT-6 gene having a 'p' value less than 0.0031 and are associated with asthma.

110. (New) The isolated allelic variant according to claim 107, wherein CA nucleotide repeat is on 17 allele of R1 locus and on 15 allele of R3 locus of the STAT-6 gene having a 'p' value less than 0.0031 and are associated with asthma.

111. (New) The isolated allelic variant according to claim 105, wherein CA nucleotide repeat is on 16 allele of R1 locus and on 15 allele of R3 locus of the STAT-6 gene

having a 'p' value less than 0.001 and are associated with asthma.

112. (New) The isolated allelic variant according to claim 107, wherein CA nucleotide repeat is on 16 allele of R1 locus and on 15 allele of R3 locus of the STAT-6 gene having a 'p' value less than 0.001 and are associated with asthma.

113. (New) The isolated allelic variant according to claim 105, wherein the percentage frequency of R1 locus dinucleotide on allele 16 is about 32% in the subjects.

114. (New) The isolated allelic variant according to claim 113, wherein the percentage frequency of R1 locus dinucleotide on allele 15 is about 30.67% in the subjects.

115. (New) The isolated allelic variant according to claim 107, wherein the percentage frequency of R3 locus dinucleotide on allele 15 is about 35% in the subjects.

116. (New) The isolated allelic variant according to claim 115, wherein the percentage frequency of R3 locus dinucleotide on allele 15 is about 32% in the subjects.

117. (New) The isolated allelic variant according to claim 105, wherein haploypes 17__14 (CA repeat 17 in R1 locus and 14 in R3 locus of the STAT-6 gene having a 'p' value less than 0.00001), 23__16 (CA repeat 23 in R1 locus and 16 in R3 locus of the STAT-6 gene having a 'p' value less than 0.00001) and 24 ___16 (CA repeat 24 in R1 locus and 16 in R3 locus of the STAT-6 gene having a 'p' value less than 0.0001) are associated with protection from asthma.

118. (New) The isolated pharmacogenetic markers having SEQ ID NOS: 1 and 2 for detecting and predicting a predisposition to atopic asthma of STAT-6 gene in a subject.

119. (New) The isolated pharmacogenetic markers according to claim 118, wherein SEQ ID NO. 1 is associated with R1 locus and SEQ ID No. 2 is associated with R3

locus of STAT-6 gene.

120. (New) The isolated pharmacogenetic markers according to claim 118, wherein a subject is human.